Hansa Biopharma AB (OSTO:HNSA) Other Current Liabilities : kr248.9 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Other Current Liabilities?

Hansa Biopharma AB's other current liabilities for the quarter that ended in Mar. 2024 was kr248.9 Mil.

Hansa Biopharma AB's quarterly other current liabilities declined from Sep. 2023 (kr288.0 Mil) to Dec. 2023 (kr224.9 Mil) but then increased from Dec. 2023 (kr224.9 Mil) to Mar. 2024 (kr248.9 Mil).

Hansa Biopharma AB's annual other current liabilities increased from Dec. 2021 (kr110.8 Mil) to Dec. 2022 (kr194.3 Mil) and increased from Dec. 2022 (kr194.3 Mil) to Dec. 2023 (kr224.9 Mil).

Hansa Biopharma AB Other Current Liabilities Historical Data

The historical data trend for Hansa Biopharma AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Other Current Liabilities Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Hansa Biopharma AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Hansa Biopharma AB Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Hansa Biopharma AB's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines